These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 8583370)

  • 1. Dihydroetorphine is a mu-receptor-selective ligand.
    Wang DX; Lu XQ; Qin BY
    J Pharm Pharmacol; 1995 Aug; 47(8):669-73. PubMed ID: 8583370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitussive effect of dihydroetorphine in mice.
    Kamei J; Iwamoto Y; Suzuki T; Misawa M; Nagase H; Kasuya Y
    Eur J Pharmacol; 1994 Aug; 260(2-3):257-9. PubMed ID: 7988653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antinociceptive effect of dihydroetorphine in diabetic mice.
    Kamei J; Suzuki T; Misawa M; Nagase H; Kasuya Y
    Eur J Pharmacol; 1995 Feb; 275(1):109-13. PubMed ID: 7774657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological study of dihydroetorphine in cloned mu-, delta- and kappa-opioid receptors.
    Katsumata S; Minami M; Nakagawa T; Iwamura T; Satoh M
    Eur J Pharmacol; 1995 Nov; 291(3):367-73. PubMed ID: 8719422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Etorphine elicits anomalous excitatory opioid effects on sensory neurons treated with GM1 ganglioside or pertussis toxin in contrast to its potent inhibitory effects on naive or chronic morphine-treated cells.
    Crain SM; Shen KF
    Brain Res; 1996 Nov; 741(1-2):275-83. PubMed ID: 9001733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydroetorphine: a potent analgesic: pharmacology, toxicology, pharmacokinetics, and clinical effects.
    Ohmori S; Morimoto Y
    CNS Drug Rev; 2002; 8(4):391-404. PubMed ID: 12481194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Opioid receptor interaction and adenylyl cyclase inhibition of dihydroetorphine: direct comparison with etorphine.
    Niwa M; al-Essa LY; Ohta S; Kohno K; Nozaki M; Tsurumi K; Iwamura T; Kataoka T
    Life Sci; 1995; 56(21):PL395-400. PubMed ID: 7739347
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etorphines: mu-opioid receptor-selective antinociception and low physical dependence capacity.
    Aceto MD; Harris LS; Bowman ER
    Eur J Pharmacol; 1997 Nov; 338(3):215-23. PubMed ID: 9424015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential binding properties of oripavines at cloned mu- and delta-opioid receptors.
    Lee KO; Akil H; Woods JH; Traynor JR
    Eur J Pharmacol; 1999 Aug; 378(3):323-30. PubMed ID: 10493109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Agonist and antagonist properties of dihydroetorphine for mu-opioid receptors in mice.
    Kamei J; Suzuki T; Nagase H
    Neurosci Lett; 1996 Sep; 215(2):87-90. PubMed ID: 8888002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Binding of [3H] dihydroetorphine to opioid receptors in rat brain membrane].
    Wang DX; Qin BY
    Zhongguo Yao Li Xue Bao; 1996 May; 17(3):281-3. PubMed ID: 9812759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some pharmacological properties of a newly synthesized 3-acetoxy-6 beta-acetylthio-10-oxo-N-cyclopropylmethyl-dihydronormorphine (KT-95).
    Hosoki R; Niizawa S; Koike K; Sagara T; Kanematsu K; Takayanagi I
    Arch Int Pharmacodyn Ther; 1996; 331(2):136-52. PubMed ID: 8937625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metopon and two unique derivatives: affinity and selectivity for the multiple opioid receptors.
    McLaughlin JP; Nowak D; Sebastian A; Schultz AG; Archer S; Bidlack JM
    Eur J Pharmacol; 1995 Dec; 294(1):201-6. PubMed ID: 8788432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous opioid peptides contribute to antinociceptive potency of intrathecal [Dmt1]DALDA.
    Szeto HH; Soong Y; Wu D; Qian X; Zhao GM
    J Pharmacol Exp Ther; 2003 May; 305(2):696-702. PubMed ID: 12606628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Attenuation of the gerbil writhing response by mu-, kappa- and delta-opioids, and NK-1, -2 and -3 receptor antagonists.
    Gallantine EL; Meert TF
    Pharmacol Biochem Behav; 2004 Sep; 79(1):125-35. PubMed ID: 15388292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
    J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unexpected antinociceptive potency of cyclic [D-Tca1]CTAP: potential for a novel mechanism of action.
    Horan PJ; Wild KD; Kazmierski WM; Ferguson R; Hruby VJ; Weber SJ; Davis TP; Fang L; Knapp RJ; Yamamura HI
    Eur J Pharmacol; 1993 Mar; 233(1):53-62. PubMed ID: 8386089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HS-599: a novel long acting opioid analgesic does not induce place-preference in rats.
    Lattanzi R; Negri L; Giannini E; Schmidhammer H; Schutz J; Improta G
    Br J Pharmacol; 2001 Sep; 134(2):441-7. PubMed ID: 11564664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Binding affinity to and dependence on some opioids in Sf9 insect cells expressing human mu-opioid receptor.
    Liu ZH; He Y; Jin WQ; Chen XJ; Zhang HP; Shen QX; Chi ZQ
    Acta Pharmacol Sin; 2003 Sep; 24(9):859-63. PubMed ID: 12956932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between the mu-agonist dermorphin and the delta-agonist [D-Ala2, Glu4]deltorphin in supraspinal antinociception and delta-opioid receptor binding.
    Negri L; Improta G; Lattanzi R; Potenza RL; Luchetti F; Melchiorri P
    Br J Pharmacol; 1995 Dec; 116(7):2931-8. PubMed ID: 8680727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.